eptacog alfa (activated)

This medicine is authorised for use in the European Union.


NovoSeven is a medicine used to treat bleeding episodes and to prevent bleeding after surgical procedures. It is used in patients with the following conditions:

  • congenital haemophilia (a bleeding disorder present from birth) who have developed or are expected to develop ‘inhibitors’ (antibodies) against factor VIII or IX;
  • acquired haemophilia (a bleeding disease caused by the development of inhibitors to factor VIII);
  • congenital factor VII deficiency;
  • Glanzmann’s thrombasthenia (a rare bleeding disorder), who cannot be treated with a transfusion of platelets (components that help the blood to clot).

The medicine is also used to treat patients with severe postpartum haemorrhage (serious bleeding after giving birth), when medicines that stimulate the muscles of the womb to contract (uterotonic medicines) are not effective at controlling the bleeding.

NovoSeven contains the active substance eptacog alfa.

This EPAR was last updated on 27/02/2023

Authorisation details

Product details
Agency product number
Active substance
eptacog alfa (activated)
International non-proprietary name (INN) or common name
eptacog alfa (activated)
Therapeutic area (MeSH)
  • Hemophilia B
  • Thrombasthenia
  • Factor VII Deficiency
  • Hemophilia A
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Novo Allé
DK-2880 Bagsværd

Product information

23/02/2023 NovoSeven - EMEA/H/C/000074 - IAIN/0119

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:

  • in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda units (BU);
  • in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-VIII or factor-IX administration;
  • in patients with acquired haemophilia;
  • in patients with congenital factor-VII deficiency;
  • in patients with Glanzmann's thrombasthenia with antibodies to platelet glycoprotein (GP) IIb-IIIa and / or human leucocyte antigens (HLA), and with past or present refractoriness to platelet transfusions.
  • in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.


Assessment history

Related content

How useful was this page?

Add your rating
2 ratings
2 ratings
1 rating